Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11086721 | 0.83 | ALDH1A1 (0.53) | CA2ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL17888162 | 0.83 | ALDH1A1 (0.53) | CA2ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL15418187 | 0.83 | ALDH1A1 (0.53) | CA2ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL9851924 | 0.83 | ALDH1A1 (0.49) | CA2ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL2219001 | 0.83 | ALDH1A1 (0.53) | CA2ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL25077639 | 0.82 | ALDH1A1 (0.62) | CA2ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL2219135 | 0.82 | ALDH1A1 (0.62) | CA2ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL2216995 | 0.82 | ALDH1A1 (0.62) | CA2ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL8819217 | 0.82 | ALDH1A1 (0.62) | CA2ALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL13996375 | 0.82 | ALDH1A1 (0.62) | CA2ALDH1A1TDP1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465876-B1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | PFAENDLER HANS RUDOLF (DE) | 2008-11-05 | — | — | EP | disclosed |
| US-20040266747-A1 | Long chain fatty alcohol substituents in antineoplastic agents | PFAENDLER HANS R (DE) | 2004-12-30 | — | — | US | disclosed |
| EP-1465876-A1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | Pfaendler, Hans Rudolf (DE) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003055864-A1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | PFAENDLER HANS RUDOLF (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266747-A1 | Long chain fatty alcohol substituents in antineoplastic agents | FASN, ELOVL3, ELOVL1 | CA2 3978/4885ALDH1A1 52/4885TDP1 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.